Lenvatinib plus pembrolizumab for the treatment of patients with non-BRAF mutated anaplastic thyroid cancer: A single center, phase 2 clinical trial
European Journal of Cancer · 2026
DOI: 10.1016/j.ejca.2026.117013 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2026. Verfasst von Maria E Cabanillas und 18 weiteren Autor:innen. Beteiligte Einrichtung: The University of Texas MD Anderson Cancer Center, Houston, TX, United States. Electronic address: mcabani@mdanderson.org. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Phenylurea Compounds, Thyroid Carcinoma, Anaplastic, Quinolines. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Gateway for Cancer Research, University of Texas MD Anderson Cancer Center.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The University of Texas MD Anderson Cancer Center, Houston, TX, United States. Electronic address: mcabani@mdanderson.org.
- The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Förderung
- Gateway for Cancer Research
- University of Texas MD Anderson Cancer Center
Zitieren
APA
Cabanillas, M. E., Busaidy, N. L., Zafereo, M., Iyer, P. C., Wang, J. R., Hamidi, S., Ferrarotto, R., Liu, S., Gunn, G. B., Spiotto, M., Lee, A., Maniakas, A., Gule-Monroe, M., Williams, M. D., Hosseini, S. M., Banuchi, V. E., Hu, M. I., Ning, M., & Dadu, R. (2026). Lenvatinib plus pembrolizumab for the treatment of patients with non-BRAF mutated anaplastic thyroid cancer: A single center, phase 2 clinical trial. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2026.117013
Vancouver
Cabanillas ME, Busaidy NL, Zafereo M, Iyer PC, Wang JR, Hamidi S, et al. Lenvatinib plus pembrolizumab for the treatment of patients with non-BRAF mutated anaplastic thyroid cancer: A single center, phase 2 clinical trial. European Journal of Cancer. 2026. doi:10.1016/j.ejca.2026.117013
BibTeX
@article{Cabanillas2026,
author = {Cabanillas, Maria E and Busaidy, Naifa L and Zafereo, Mark and Iyer, Priyanka C and Wang, Jennifer R and Hamidi, Sarah and Ferrarotto, Renata and Liu, Suyu and Gunn, Gary B and Spiotto, Michael and Lee, Anna and Maniakas, Anastasios and Gule-Monroe, Maria and Williams, Michelle D and Hosseini, S Mohsen and Banuchi, Victoria E and Hu, Mimi I and Ning, Matthew and Dadu, Ramona},
title = {Lenvatinib plus pembrolizumab for the treatment of patients with non-BRAF mutated anaplastic thyroid cancer: A single center, phase 2 clinical trial},
journal = {European Journal of Cancer},
year = {2026},
doi = {10.1016/j.ejca.2026.117013}
}
EUVIMED